Research and Markets (http://www.researchandmarkets.com/research/tqhjjg/global_orphan) has announced the addition of the "Global Orphan Drugs Market Outlook 2020" report to their offering.

The number of diseases for which no treatment is currently available is estimated to be between 4,000 to 5,000, worldwide. The patent expiry of blockbuster drugs and increased competition from generics has shifted the focus of pharmaceutical industry from the essential medicines to orphan drugs.

Incentives for drug development provided by governments, as well as support from the regulatory bodies, are a further boost for the companies developing orphan drugs all over the world.

The orphan drug market is anticipated to reach around US$ 180 Billion by 2020. The report provides a detailed analysis of the market for these orphan drugs.

An estimation of the market potential of these drugs has been done keeping in mind that many more of these drugs are being tested in clinical trials for various indications, apart from the ones that are already approved. Furthermore, the report also provides the revenue generated by top 10 orphan drugs in 2014.

Companies Mentioned:

  • AbbVie
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis
  • Pfizer Inc.
  • Sanofi

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Orphan Drug - An Introduction

4. Drivers and Challenges

5. Global Orphan Drug Market - Overview

6. Market Segmentation

7. Current Status of Orphan Drugs in Pipeline

8. Trends and Developments

9. Mergers and Acquisitions

10. Regulatory Scenario

11. Competitive Landscape

12. Key Player Analysis

13. Opportunities & Recommendation

For more information visit http://www.researchandmarkets.com/research/tqhjjg/global_orphan